Eli Lilly and Company (NYSE:LLY) is moving quickly to lock in its position in India’s fast-growing obesity drug market.
The listed firm is a Detroit-based fintech platform that owns mortgage, real estate, and personal finance businesses, namely ...
On December 10, Deutsche Bank analyst George Hill raised the firm’s price target on McKesson Corporation (NYSE:MCK) to $904 ...
Amgen Inc. (NASDAQ:AMGN) has outperformed the broader market this year, supported by strong financial results and steady ...
On December 26, Johnson & Johnson (NYSE:JNJ) said it ended a mid-stage study of an experimental drug for patients with ...
On December 17, the US Food and Drug Administration moved to fast-track reviews of two experimental Merck & Co., Inc.
On December 15, BofA lowered the firm’s price target on AbbVie Inc. (NYSE:ABBV) to $233 from $248 and kept a Neutral rating.
On December 9, Barclays analyst Glen Santangelo initiated coverage of Viatris Inc. (NASDAQ:VTRS) with an Overweight rating ...
On December 22, Abbott Laboratories (NYSE:ABT) said the US Food and Drug Administration has approved the company’s Volt™ PFA ...
On December 19, BofA analyst Peter Galbo raised the price target on The Coca-Cola Company (NYSE:KO) to $85 from $80 and kept ...
On December 19, BofA raised its price target on Colgate-Palmolive Company (NYSE:CL) to $90 from $88 and kept a Buy rating.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback